Argenx
ARGX
$923.40
Share price
6.36%
Change (1 day)
59.08%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
Earnings for Argenx (ARGX)
Earnings in 2024 (TTM): A$0.12 Billion
According to Argenx 's latest financial reports the company's current earnings are A$2.19 Billion. , an increase over its 2023 earnings that were of -A$0.49 Billion. The earnings displayed on this page is the company's Pretax Income.
Earnings history for Argenx from 2013 to 2024
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2024  | A$0.13 B | -127.97% |
| 2023 | -A$0.49 Billion | -58.25% |
| 2022 | -A$1.16 Billion | |
| 2019 | -A$0.32 Billion | 124.95% |
| 2018 | -A$0.15 Billion | 132.04% |
| 2017 | -A$60.62 Million | 54.86% |
| 2016 | -A$39.15 Million | 33% |
| 2015 | -A$29.44 Million | 13.63% |
| 2014 | -A$25.91 Million | 46.25% |
| 2013 | -A$17.72 Million |